Patrick A. Flume

17.2k total citations · 6 hit papers
241 papers, 9.6k citations indexed

About

Patrick A. Flume is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Physiology. According to data from OpenAlex, Patrick A. Flume has authored 241 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 190 papers in Pulmonary and Respiratory Medicine, 57 papers in Epidemiology and 20 papers in Physiology. Recurrent topics in Patrick A. Flume's work include Cystic Fibrosis Research Advances (167 papers), Tracheal and airway disorders (46 papers) and Inhalation and Respiratory Drug Delivery (42 papers). Patrick A. Flume is often cited by papers focused on Cystic Fibrosis Research Advances (167 papers), Tracheal and airway disorders (46 papers) and Inhalation and Respiratory Drug Delivery (42 papers). Patrick A. Flume collaborates with scholars based in United States, United Kingdom and Australia. Patrick A. Flume's co-authors include J.S. Elborn, Bruce C. Marshall, Karen A. Robinson, Peter J. Mogayzel, Christopher H. Goss, Randall L. Rosenblatt, David E. Geller, Donald R. VanDevanter, Michael W. Konstan and Kenneth N. Olivier and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Patrick A. Flume

227 papers receiving 9.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR

2015 1.2k citations J.S. Elborn, K. De Boeck et al. profile →
Cystic Fibrosis Pulmonary Guidelines

2007 765 citations Patrick A. Flume, Christopher H. Goss et al. American Journal of Respiratory and Critical Care Medicine profile →
Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations

2009 522 citations Patrick A. Flume, Christopher H. Goss et al. American Journal of Respiratory and Critical Care Medicine profile →
European Cystic Fibrosis Society Standards of Care: Best Practice guidelines

2014 371 citations Alan R Smyth, Scott C. Bell et al. Journal of Cystic Fibrosis profile →
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

2012 365 citations Patrick A. Flume, J.S. Elborn et al. Journal of Cystic Fibrosis profile →
Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity

2018 269 citations Patrick A. Flume, James D. Chalmers et al. profile →

Peers

Countries citing papers authored by Patrick A. Flume

Since Specialization

Citations

This map shows the geographic impact of Patrick A. Flume's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick A. Flume with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick A. Flume more than expected).

Fields of papers citing papers by Patrick A. Flume

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick A. Flume. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick A. Flume. The network helps show where Patrick A. Flume may publish in the future.

Co-authorship network of co-authors of Patrick A. Flume

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick A. Flume. A scholar is included among the top collaborators of Patrick A. Flume based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick A. Flume. Patrick A. Flume is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Study Design of a Phase III Study (AIRTIVITY®) of the Novel Cathepsin C (Dipeptidyl Peptidase 1) Inhibitor BI 1291583 in People With Bronchiectasis 2025 ·American Journal of Respiratory and Critical Care Medicine ·James D. Chalmers, Michal Shteinberg, Sanjay H. Chotirmall, (unknown), Patrick A. Flume, Raksha Jain, (unknown), Anne E. O’Donnell, Felix C. Ringshausen, (unknown), Jin‐Fu Xu, (unknown), (unknown), (unknown), Marcus Mall, Pamela J. McShane	1
2	A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria 2025 ·European Respiratory Review ·Charles L. Daley, Patrick A. Flume, Jakko van Ingen, Reeti Khare, (unknown), Minh-Vu H Nguyen, Kevin Winthrop, Beth Shoshana Zha	0
3	Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy 2024 ·CHEST Journal ·Raksha Jain, (unknown), MinJae Lee, Ashley Keller, (unknown), (unknown), Natalie E. West, Traci M. Kazmerski, Jennifer L. Goralski, Patrick A. Flume, Andrea H. Roe, Denis Hadjiliadis, Ahmet Uluer, Sheila K. Mody, Sigrid Ladores, Jennifer L. Taylor‐Cousar	9
4	Cystic fibrosis foundation position paper: Redefining the cystic fibrosis care team 2024 ·Journal of Cystic Fibrosis ·Rebekah F. Brown, (unknown), (unknown), (unknown), Danielle Goetz, Stephanie S. Filigno, (unknown), Quynh T. Tran, Sarah E. Hempstead, Paula Lomas, Alison Brown, Patrick A. Flume	12
5	The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis, 2024 ·Journal of Cystic Fibrosis ·Margaret Rosenfeld, Elizabeth A. Cromwell, Michael S. Schechter, Clement L. Ren, Patrick A. Flume, Rhonda D. Szczesniak, Wayne J. Morgan, Raksha Jain	8
6	Pulmonary exacerbations in insured patients with bronchiectasis over 2 years 2023 ·ERJ Open Research ·Patrick A. Flume, (unknown), Matthew Lucci, Jasmanda Wu, (unknown), Mariam Hassan, Anjan Chatterjee	6
7	14 Spontaneous changes to airway microbiology after initiation of elexacaftor-tezacaftor-ivacaftor in people with advanced cystic fibrosis lung disease 2023 ·Journal of Cystic Fibrosis ·Mark E. Mullins, (unknown), Limor Cohen, (unknown), (unknown), Patrick A. Flume, Stefanie Krick, Kadambari Vijaykumar, Bryan Garcia	1
8	Role of hyperglycemia in cystic fibrosis pulmonary exacerbations 2023 ·Journal of Cystic Fibrosis ·(unknown), Aniket Sidhaye, Phuong T. Vu, Sonya L. Heltshe, Christopher H. Goss, Patrick A. Flume, Andrea Kelly, Margaret Rosenfeld	1
9	Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis 2023 ·Respiratory Medicine ·Patrick A. Flume, Ashwin Basavaraj, Bryan Garcia, Kevin Winthrop, (unknown), Charles L. Daley, Julie V. Philley, Emily Henkle, Anne E. O’Donnell, Mark L. Metersky	8
10	Factors associated with receiving CF care and use of telehealth in 2020 among persons with Cystic Fibrosis in the United States 2022 ·Journal of Cystic Fibrosis ·(unknown), Dana Albon, (unknown), Patrick A. Flume, (unknown), Elizabeth A. Cromwell	2
11	Overcoming non-compliance with clinical trial registration and results reporting: One Institution's approach 2020 ·Contemporary Clinical Trials Communications ·(unknown), Patrick A. Flume, (unknown), (unknown), (unknown), Susan C. Sonne	9
12	Antimicrobial resistance: Concerns of healthcare providers and people with CF 2020 ·Journal of Cystic Fibrosis ·Wendy Bullington, Sarah E. Hempstead, Alan R Smyth, Pavel Dřevı́nek, Lisa Saiman, Valerie J. Waters, Scott C. Bell, Donald R. VanDevanter, Patrick A. Flume, J.S. Elborn, Marianne S. Muhlebach	12
13	GLPG2222 in CF subjects homozygous for F508DEL : results from a phase II study (FLAMINGO) 2018 ·Ghent University Academic Bibliography (Ghent University) ·(unknown), Predrag Minić, Stijn Verhulst, Eva Van Braeckel, Patrick A. Flume, Steven R. Boas, David H. Geller, Herman de Kock, (unknown), Kai-Christian Müller, (unknown), Katja Conrath, (unknown)	1
14	Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients 2018 ·American Journal of Respiratory and Critical Care Medicine ·David E. Griffith, Gina Eagle, Rachel Thomson, Timothy R. Aksamit, Noriko Hasegawa, (unknown), Doreen Addrizzo‐Harris, Anne E. O’Donnell, Theodore K. Marras, Patrick A. Flume, Michael R. Loebinger, Lucy Morgan, Paola Castellotti, A. T. Hill, Stephen J. Ruoss, Jae‐Joon Yim, Felix C. Ringshausen, Stephen K. Field, James Nezamis, Kevin Winthrop	1
15	P080 Potential taste disturbance is largely mild and diminishes with continuing treatment in cystic fibrosis patients treated with levofloxacin inhaled solution 2018 ·Journal of Cystic Fibrosis ·Christoph Schwarz, (unknown), Patrick A. Flume, J.S. Elborn	4
16	Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease 2016 ·American Journal of Respiratory and Critical Care Medicine ·Kenneth N. Olivier, David E. Griffith, Gina Eagle, John P. McGinnis, (unknown), (unknown), Charles L. Daley, Kevin Winthrop, Stephen J. Ruoss, Doreen Addrizzo‐Harris, Patrick A. Flume, Daniel Dorgan, Matthias Salathé, Barbara A. Brown‐Elliott, Renu Gupta, Richard J. Wallace	169
17	Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB) 2013 ·European Respiratory Journal ·Alan R. Barker, Anne O’Donnell, Philip J. Thompson, Patrick A. Flume, (unknown), Javier de Gracia, Wim Boersma, Eva Polverino, Lixin Shao, Jenny Zhang, (unknown), (unknown), Matt McKevitt, A. Bruce Montgomery, Alexandra L. Quittner, David Gossage, Thomas G. O’Riordan	10
18	78 Combined data from two phase III studies of Bronchitol (inhaled dry powder mannitol) in adult cystic fibrosis (CF) patients 2011 ·Journal of Cystic Fibrosis ·Diana Bilton, Moira L. Aitken, Patrick A. Flume, David E. Geller, Allen Lapey, Jonathan B. Zuckerman, K. De Boeck, G. Bellon, Helge Hebestreit, (unknown), Paul D. Robinson, Patricia Cooper, John Kolbe, John C. Gallagher, Herbert Fox, B. Charlton	2
19	Effects of inhaled MP-376 (aeroquin, levofloxacin inhalation solution) on lung function in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection 2010 ·Journal of Cystic Fibrosis ·Patrick A. Flume, David E. Geller, (unknown), Doris Staab, R. Fischer, Joachim Riethmüller, J. Loutit, Douglas Conrad	18
20	Impact of lung transplantation on site of death in cystic fibrosis 2007 ·Journal of Cystic Fibrosis ·Dee W. Ford, Patrick A. Flume	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact